Endo shares boosted by new CEO, upbeat guidance
Shares of Endo International (NASDAQ: ENDP) surged as much as 18 percent after the company named a new CEO and projected upbeat full-year earnings.
The special pharmaceutical company said Paul Campanelli, president of Par Pharmaceutical, Endo's generic and over-the-counter drugs business, will serve as CEO effective immediately.
Endo said that Par "significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market," during Campanelli's tenure.
Endo also said it expects adjusted full-year earnings between $4.50 and $4.80 per share on revenue between $3.87 billion and $4.03 billion. Those numbers are slightly more optimistic than analyst projections for earnings between $4.44 and $4.68 per share on $3.86 billion and $4.04 billion in revenue, according to Thomson Reuters consensus estimates.
Even with Friday's gains, Endo shares have plunged nearly 62 percent so far this year.
More From CNBC
Top News and Analysis
Latest News Video
Personal Finance